1. 国家自然科学基金委员会，面上项目，GSDMD调节自噬介导中性粒细胞IL-1β分泌和心梗后免疫应答的分子机制;

2. 国家自然科学基金委员会，联合科研资助基金，心脏保护学：从临床回溯实验室；

3. 国家自然科学基金委员会，优秀青年科学基金，中西医结合防治冠心病；

4. 国家自然科学基金委员会，面上项目，CaMKII O-GlcNac糖基化在糖尿病心肌缺血再灌注损伤中的作用及机制研究；

5. 国家重点研发计划，冠心病（心绞痛-心肌梗死-心衰）中医药防治方案的循证优化及疗效机制；

6. 国家中医药管理局，人才项目，青年岐黄学者。

1. Zhang R, Xiang Y*, Yang Y*. Passing Behavior of Oligonucleotides through a StackedDNA Nanochannel with Featured Path Design. J Am Chem Soc. 2024;146(25):17122-17130.

2. Li S, Wang K, Jiang K, Xing D, Deng R, Xu Y, Ding Y, Guan H, Chen LL, Wang D, ChenY*, Bu W*, Xiang Y*. Brazilin-Ce nanoparticles attenuate inflammationby de/anti-phosphorylation of IKKβ. Biomaterials. 2024;305:122466.

3. Jiang K, Hwa J, Xiang Y*. Novel strategies for targeting neutrophilagainst myocardial infarction. Pharmacol Res. 2024;205:107256.

4. Xu Y, Jiang K, Su F, Deng R, Cheng Z, Wang D, Yu Y, Xiang Y*. A transient wave of Bhlhe41+ residentmacrophages enables remodeling of the developing infarcted myocardium. CellRep. 2023;42(10):113174.

5. Xu Y, Zhang C, Jiang K, Yang X, Chen F, Cheng Z, Zhao J, Cheng J, Li X, Chen X, Zhou L, Duan H, Huang Y*, XiangY*, Li J*. Structural repurposing of SGLT2 inhibitor empagliflozin forstrengthening anti-heart failure activity with lower glycosuria. Acta PharmSin B. 2023;13(4):1671-1685. （封面论文）

6. Li Y, Tu Z, Chen F, Yang X,Deng R, Su F, Cheng Z, Li S, Ong SB, Wang D, Chen Y, Xiang Y*.Anti-inflammatory effect of Danhong injection through inhibition of GSDMD-mediatedpyroptosis. Phytomedicine. 2023;113:154743.

7. Xu Y, Jiang K, Chen F, Qian J, Wang D, Wu Y, Zhou C, Yu Y, Chen K, Hwa J, Yang B, Wang H, Xiang Y*.Bone marrow-derived naïve B lymphocytes improve heart function after myocardialinfarction: a novel cardioprotective mechanism for empagliflozin. Basic ResCardiol. 2022;117(1):47.

8. Jiang K, Tu Z, Chen K, Xu Y, Chen F, Xu S, Shi T, Qian J, Shen L, Hwa J, Wang D, Xiang Y*.Gasdermin D inhibition confers antineutrophil-mediated cardioprotection in acutemyocardial infarction. J Clin Invest. 2022;132(1):e151268. （高被引论文）

9. Jiang K, Xu Y, Wang D, Chen F, Tu Z, Qian J, Xu S, Xu Y, Hwa J, Li J, Shang H, Xiang Y*. Cardioprotectivemechanism of SGLT2 inhibitor against myocardial infarction is through reductionof autosis. Protein Cell. 2022;13(5):336-359.（封面论文）

10. Fu L, Xie C, Jin Z, Tu Z,Han L*, Jin M*, Xiang Y*, Zhang A*. The prokaryotic Argonaute proteinsenhance homology sequence-directed recombination in bacteria. Nucleic AcidsRes. 2019;47(7):3568-3579.

11. Wang D, Hu X, Lee SH, Chen F, Jiang K, Tu Z, Liu Z, Du J, Wang L, Yin C, Liao Y, Shang H, Martin KA, HerzogRI, Young LH, Qian L*, Hwa J*, Xiang Y*. Diabetes Exacerbates MyocardialIschemia/Reperfusion Injury by Down-Regulation of MicroRNA and Up-Regulation ofO-GlcNAcylation. JACC Basic Transl Sci. 2018;3(3):350-362.

12. Xiang Y*,Cheng J, Wang D, Hu X, Xie Y, Stitham J, Atteya G, Du J, Tang WH, Lee SH, LeslieK, Spollett G, Liu Z, Herzog E, Herzog RI, Lu J, Martin KA, Hwa J*. Hyperglycemiarepression of miR-24 coordinately upregulates endothelial cell expression and secretionof von Willebrand factor. Blood. 2015;125(22):3377-87.（封面焦点论文）

13. Xiang Y,de Groot R, Crawley JT, Lane DA*. Mechanism of von Willebrand factor scissile bondcleavage by a disintegrin and metalloproteinase with a thrombospondin type 1 motif,member 13 (ADAMTS13). PNAS. 2011;108(28):11602-7.

14. Xiang Y*,Xia Y, Gao XM, Shang HC, Kang LY, Zhang BL. Platelet activation, and antiplatelettargets and agents: current and novel strategies. Drugs. 2008;68(12):1647-64.